Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

295

HTML

2568

Figures (1-1)

137

Tables (1-4)

135

Sum=3135

Feb 7, 2012 (publication date) through May 1, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 7, 2012; 18(5): 466-471
Published online Feb 7, 2012. doi: 10.3748/wjg.v18.i5.466

Table 2 Efficacy results of thalidomide

Overall objective response, n = 53, (%)
CR	1 (2.9)
PR	5 (9.4)
SD	9 (17.0)
PD	38 (44.1)
Objective response rate	6 (11.3), 95% CI: 4.3-23.0
Disease control rate	15 (28.3), 95% CI: 17.8-42.4
Overall survival, mo
Median	10.5, 95% CI: 6.9-23.3
1-year survival	(45)
2-year survival	(20)
A decrease in AFP > 50% after treatment
Yes	16 (30.2)
No	37 (69.8)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; AFP: Alpha fetoprotein.

Citation: Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. World J Gastroenterol 2012; 18(5): 466-471
URL: https://www.wjgnet.com/1007-9327/full/v18/i5/466.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i5.466